Lasa Supergenerics Ltd
Lasa Supergenerics Ltd Live Price Chart
Performance
| Previous Close | ₹ |
| High | ₹ |
| Volume | |
| 52W Range | ₹ - ₹ |
| Open | ₹ |
| Low | ₹ |
| Market Cap | ₹ 27 Cr |
Lasa Supergenerics Ltd Technicals
| 20 Day | ₹ 6.239 |
| 50 Day | ₹ 6.788 |
| 100 Day | ₹ 7.248 |
| 200 Day | ₹ 8.558 |
| 20 Day | ₹ 5.483 |
| 50 Day | ₹ 6.854 |
| 100 Day | ₹ 7.120 |
| 200 Day | ₹ 7.796 |
Lasa Supergenerics Ltd Fundamentals
| ROCE | -22.206 |
| P/E Ratio | -1.520 |
| P/B Ratio | 0.510 |
| Industry P/E | 0.510 |
| Debt to Equity | 49.856 |
| ROE | -26.304 |
| EPS | -3.300 |
| Dividend Yield | 0.000 |
| Book Value | 9.905 |
| Face Value | 10.000 |
Lasa Supergenerics Ltd Financials
| Particulars | Y202603 | Y202503 | Y202403 | Y202303 | Y202203 |
|---|---|---|---|---|---|
| Total Revenue | 25.3405 | 147.4603 | 104.4343 | 131.3724 | 137.4014 |
| Total Expenses | 38.9107 | 151.1743 | 114.7737 | 153.7409 | 135.6803 |
| Profit After Tax | -34.0903 | -14.7573 | -21.7306 | -38.6207 | -5.3313 |
Lasa Supergenerics Ltd Shareholding Pattern
| Promoter Holdings | 53.651 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 42.038 % |
| Others - | 4.312 % |
About Lasa Supergenerics Ltd
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. The Company launched two new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It got huge demand all over the globe as it is manufactured and have strong entry barriers. The Scheme of Amalgamation of Harishree Aromatics and Chemicals Private Limited with the Company and their respective shareholders was approved by Hon'ble National Company Law Tribunal on December 23, 2022 which became effective from January 04, 2023 in year 2022-23. Following the said Scheme of Amalgamation, 1000 Equity Shares of Rs ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 35.31 -0.22 (-0.62%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 493.20 +0.2 (+0.04%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 6,299.00 +62 (+0.99%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 680.90 +32.4 (+5%) |
| Abbott India Ltd Pharmaceuticals | ₹ 26,145.00 -130 (-0.49%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,358.00 -7.6 (-0.56%) |
FAQs on Lasa Supergenerics Ltd
1. Can I buy Lasa Supergenerics Ltd from PL Capital? ›
2. Does Lasa Supergenerics Ltd pay dividends? ›
3. What is the current share price of Lasa Supergenerics Ltd ? ›
4. What is the 52-week high and low of Lasa Supergenerics Ltd ? ›
5. What is the market capitalisation of Lasa Supergenerics Ltd? ›
6. What is the current P/E ratio of Lasa Supergenerics Ltd? ›
7. What is the current P/B ratio of Lasa Supergenerics Ltd? ›
8. What is the shareholding pattern of Lasa Supergenerics Ltd? ›
9. What is the 1-year return of Lasa Supergenerics Ltd? ›
Start SIP in Lasa Supergenerics Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
